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Abstract
Objective To evaluate whether the potential of statins to lower the risk
of infections as published in observational studies is causal.
Design Systematic review and meta-analysis of randomised placebo
controlled trials.
Data sources Medline, Embase, and the Cochrane Library.
Study selection Randomised placebo controlled trials of statins (up to
10 March 2011) enrolling a minimum of 100 participants, with follow-up
for at least one year.
Data extraction Infection or infection related death.
Results The first study selection yielded 632 trials. After screening of
the corresponding abstracts and full text papers, 11 trials totalling 30
947 participants were included. 4655 of the participants (2368 assigned
to statins and 2287 assigned to placebo) reported an infection during
treatment. Meta-analysis showed no effect of statins on the risk of
infections (relative risk 1.00, 95% confidence interval 0.96 to 1.05) or
on infection related deaths (0.97, 0.83 to 1.13).
Conclusion These findings do not support the hypothesis that statins
reduce the risk of infections. Absence of any evidence for a beneficial
effect in large placebo controlled trials reduces the likelihood of a causal
effect as reported in observational studies.
Introduction
Statins (hydroxymethyl glutaryl coenzyme A (HMG-CoA)
reductaseinhibitors),drugsusedtolowercholesterollevels,are
prescribed frequently and their cardiovascular benefits are
widely accepted in medical practice. In addition to cholesterol
lowering effects, statins have anti-inflammatory and
immunomodulatory properties, so called pleiotropic effects.
Such effects might be beneficial in the management of
infections.
1-3
Whether statins can help to prevent infection is still debated.
Since2006,populationbasedobservationalstudieshavereported
associations between statins and a reduced risk of infectious
outcomes such as pneumonia and sepsis and infection related
mortality, with preventive effects up to 76%.
4-10 However, the
possibility of biased estimations of effect, which are inherent
in observational studies, cannot be excluded. Recently, some
investigatorssuggestedthattheprotectiveassociationsreported
in many of these studies could reflect bias from “healthy user”
effects—that is, that statin users tend to have less severe
comorbidity and better functional status than non-users and are
more likely to practise other healthy behaviours. Despite
extensiveeffortstominimisealltypesofconfoundingandother
biases, the effects of statins on risk of infection are
inconclusive.
11 12
Wehypothesisedthatifapreventiveeffectofstatinsontherisk
of infections existed it should be detectable in the data of large
placebo controlled trials. Considering the placebo controlled
nature of such trials this would mean a true effect. We carried
outasystematicreviewandmeta-analysisofplacebocontrolled
trials of statins to evaluate whether the beneficial association
betweenstatinsandinfectionspublishedinobservationalstudies
is causal.
Methods
We carried out a systematic review and meta-analysis of
published trials according to the preferred reporting items for
Correspondence to: E M W van de Garde e.van.de.garde@antoniusziekenhuis.nl
Extra material supplied by the author (see http://www.bmj.com/content/343/bmj.d7281?tab=related#webextra)
Details of contact with authors
Details of participants’ characteristics
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d7281 doi: 10.1136/bmj.d7281 (Published 29 November 2011) Page 1 of 10
Research
RESEARCHsystematic reviews and meta-analyses (PRISMA) guidelines.
13
A systematic search of Medline in PubMed, Embase, and the
Cochrane Library database (the Cochrane central register of
controlledtrials)forstudiesreportinganinfectionasanadverse
event or cause of death related to statin use was done from
inceptionto10March2011.Toidentifyfurtherarticleswehand
searched references and the related citations in PubMed.
We included randomised controlled trials reported in English
only. Search terms, MeSH subject headings, and limits were
“hydroxymethylglutaryl-CoA reductase inhibitors”,
“anticholesteremic agents”, “statin”, “simvastatin”,
“rosuvastatin”, “pravastatin”, “atorvastatin”, “fluvastatin”,
“cerivastatin”,“pitavastatin”,“lovastatin”,“placebocontrolled”,
and “randomised controlled trial”.
Inclusion and exclusion criteria
Allcapturedpublicationswerescreenedaccordingtopredefined
selection criteria. We included all randomised controlled trials
with a statin as active treatment and a placebo as comparator.
Eligible studies had a follow-up period of at least 12 months, a
minimum of 100 participants, and reported on infections or
infection related mortality. We excluded duplicate
publications—that is, two or more studies that investigated the
same sample.
Afterthefirstautomatedqueryinthedatabases,weusedathree
step process for screening. Firstly, we screened the abstracts.
Secondly, we screened the remaining publications on the basis
ofthecorrespondingfulltextpublicationforreportsonadverse
events and causes of death. Finally, we screened the articles
withinformationonadverseeventsandmortalityforreportson
the occurrence of infections or infection related mortality.
Besides the predefined search strategy, one reviewer (HLvdH)
considered trials that had been excluded in the final step for not
reporting infections as of potential importance when extensive
data on other adverse events were available. The principal
investigators of these trials were then contacted for
supplementary data.
Data extraction
One reviewer (HLvdH) extracted the data. From each eligible
publication data were captured on first author, year of
publication, title, journal, study population, primary study
outcome, duration of follow-up, number of participants in each
group (statin and placebo groups), and type and dose of statin
studied. From each included study HLvdH extracted data on
the occurrence of infections as adverse events and data on
infection related mortality.
Quality and risk of bias assessment
Using the Cochrane risk of bias tool we screened all captured
trials for quality of study design, including randomisation,
blinding, withdrawal, and dropouts.
14 Because we studied
unexpected “adverse” events in this systematic review we
focused our assessment on quality of reporting adverse events
and withdrawal of treatment in both study arms. Withdrawal of
treatment was considered to rule out the possibility that
differences in denominators may explain differences in
calculated infection rates.
Statistical analysis
Statistical analysis of the dichotomous variables was carried
outusingrelativeriskasthesummarystatistic.Weusedrandom
effectmodellingbyDerSimonian-Lairdforanalysisandreported
results in a forest plot with 95% confidence intervals. The
relativerisksrepresentedtheriskofanadverseeventhappening
during study interval in participants taking a statin compared
with those taking a placebo. When possible we carried out
subgroup analyses and stratified the results for type of statin,
statin dosage, patients’ characteristics, and type of infection. A
relative risk of less than 1 would favour the statin treated
population;weconsideredthepointestimateoftherelativerisk
to be significant at the P<0.05 level if the confidence interval
did not include the value 1. Heterogeneity was analysed using
the Cochran Q test (χ
2) and I
2 statistics as a complement to the
Qtest.
15 16I
2istheproportionoftotalvariationobservedbetween
the trials attributable to differences between trials rather than
to sampling error (chance), with values less than 30%
representing low variation, less than 60% moderate variation,
and greater than 60% high variation. Analyses were done with
PASW Statistics 18.0 for Windows (SPSS). We carried out
additional sensitivity analysis to explore the influence of the
quality and risk of bias found in the included trials.
Results
The first database query yielded 607 publications (fig 1⇓).
Another 25 studies were identified by hand searching. After
removalofduplicates,theremaining587articleswerescreened
on the basis of the title and abstract. Only 135 trials fulfilled
the inclusion criteria. These trials were further evaluated for
reporting on the incidence of adverse events and mortality. Of
the 39 trials reporting adverse events and causes of death, 10
publications had information on infections. Additionally, 13
trialswerecertifiedaspotentiallyrelevantandtheauthorswere
contacted for primary and supplementary information (see web
extra). Of these 13 trials, only one study group provided
additional information. In total, the final selection comprised
11 trials. Analyses were carried out on these 11 trials.
Baseline characteristics
Table1⇓summarisesthebaselinecharacteristicsoftheincluded
trials. The 11 trials randomised 30 947 participants: 14 103
(45.6%) received statin therapy and 16 844 (54.4%) received
placebo. The average follow-up was 3.3 (range 1-5.1) years.
The mean age of the patients was 63 (range 48 to 73) years (see
web extra).
Of the 11 randomised controlled trials, one was not double
blinded (table 2⇓). Three of the trials stated they were
randomised but did not give the specific method of sequence
generation, although they did state that investigators and
participants were blinded to the process of randomisation.
Except for one trial,
17 study quality was satisfactory overall and
the trials were judged to be at low risk of bias (adequate
sequencegenerationorallocationconcealment,doubleblinding,
and clear reporting of withdrawal rates and loss to follow-up).
All trials were based on intention to treat analysis of long term
treatments. The original publications of the trials included in
this meta-analysis reported that 1.1-34.6% of participants
assigned to statins had stopped using the drugs by the end of
follow-up, similar to the 1.0-44.2% of participants assigned to
placebo.
Occurrence of infections
Data on infection related adverse events and infection related
mortality were retrieved from the original publications, except
for the GISSI–heart failure trial
21 where the authors provided
the relevant data on request. In total, 4655 patients experienced
an infection during treatment, reported as an adverse event or
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RESEARCHcause of death. Of these patients, 2368 were assigned to statins
and2287toplacebo.Table3⇓providesdetailsoftheindividual
trials. Most did not report the site of infection.
Statin treatment and outcome events
In meta-analysis the use of statins was not associated with a
decreaseintheriskofinfectionrelatedadverseeventscompared
with placebo (relative risk 1.00, 95% confidence interval 0.96
to 1.05; P=0.93, fig 2⇓). Heterogeneity of the included studies
was low (I
2=5.5%). Similarly, statins were not associated with
a reduction in the risk of infection related mortality (0.97, 0.83
to 1.13; P=0.71, fig 3⇓). The included studies also showed low
heterogeneity (I
2=18.8%). In sensitivity analysis the exclusion
of data from the trial lacking double blinding
17 did not
significantlyaltertheresultsforinfectionrelatedmortality(0.98,
0.84 to 1.14).
Discussion
In this systematic review and meta-analysis of data from
randomised placebo controlled trials of statins, we found no
evidence to support the hypothesis that statins decrease the risk
of infection. We pooled the data of 30 947 participants, giving
arelativeriskof1.00forinfectionsand0.97forinfectionrelated
mortality. Absence of any evidence towards a beneficial effect
of statins on risk of infection in large placebo controlled statin
trials does not support a causal protective association between
statins and infections as reported in observational studies.
Comparison with other studies
Ourresultsdifferfromthoseofmostoftheobservationalstudies
that examined use of statins and risk of infections. Since 2006,
observational studies have reported a possible beneficial effect
of statins on risk of infection.
43 44 Many such studies showed
beneficial effects, but a study by Majumdar et al was the first
tointroducethesocalledhealthyusereffectasapossiblesource
of bias in these studies. Although these researchers studied the
effects of statins on prognosis of infections, their findings that
analyses with more thorough adjustment, including for
functional status, showed no association might also extend to
prevention of infections.
11 In 2009 a study reported that statin
usewasnotassociatedwithadecreasedriskofpneumoniawhen
adjusted for measures of functional or cognitive state.
12 More
recently, statins have been linked to an increased risk of
infection after stroke and no evidence of an effect on risk of
invasive mould infection.
45 46
A major methodological difference between these studies and
our study may explain the divergent results. Most importantly,
andinherenttothestudydesign,observationalstudiesarealways
at risk of unmeasured confounding. A major strength of our
meta-analysis of data from only randomised controlled trials is
the absence of such bias. The so called healthy user effect, for
example, should be absent when allocation to statin treatment
or to placebo is determined by chance. Given that our study
showed an effect size of about zero provides evidence that
previous findings from observational studies indeed might be
biased.
Although it is likely that results from the trials were correct and
analyses from observational studies were biased, the reverse
scenario is also plausible. Firstly, the reporting of infections
was limited and most researchers did not provide additional
data on request. Therefore we might have included a
non-representative sample of statin trials for infectious
outcomes.However,thelackofeffectreportedinthepublished
trials would be biased only in the unlikely scenario of
preferential publication of null findings. Secondly, we cannot
rule out the possibility that statins still might be beneficial in
some categories of patients. Although our meta-analysis
provided no suggestion for a specific subgroup with reduced
riskofinfection,thismightbemissedbecauserandomisedtrials
in general include “healthier” people with fewer comorbidities
and drugs used concurrently. On the other hand, most of the
participantsinthismeta-analysishadrenaldiseaseanddiabetes,
two known risk factors for infections, and comparable to the
type of patients largely present in many of the observational
studies showing a large beneficial effect, whereas our study
found a null effect. Also, the mean age of the patients in the
present meta-analysis did not differ from the available
observational studies (63 years v 63 years).
In the present study we focused on the effects of statins on risk
ofinfection.Weknowthatalargeamountofobservationaldata
exists suggesting acute statin effects to improve the prognosis
of infection. In our opinion, prevention and treatment effects
are both important, but they are clearly different. It is not
inconceivable that statins influence the inflammatory response
in the acute phase of infection without affecting the overall risk
of acquiring infection. According to Clinicaltrials.gov, several
randomised clinical trials of statins in the setting of sepsis and
pneumonia are currently under way. The findings from these
trials will help to answer what statins can add to our shared
effort to improve the prognosis of infection.
Strengths and limitations of the study
Strengths of our study include the effort to minimise
confounding and the alternative approach used. Firstly, we
carried out a thorough systematic review of all placebo
controlledtrialsofstatinsfordataonthepresenceofinfections.
Thiswasfollowedbyameta-analysistoanalyseunbiasedstatin
effects on the risk of acquiring infections. This alternative
approachprovidesauniquechancetoexploretheheterogeneity
among the observational studies on the subject. This approach
has also been applied to explore the reporting of statins and
their effects on risk of fracture.
47
Our study also has some limitations. Mainly, of the 632
publications screened only 11 trials reported on the incidence
of infections. Therefore we were unable to carry out subgroup
analyses for statin dose, type of statin, patients’ characteristics,
and type of infection. Secondly, we have no information on the
validityoftheinfectiousoutcomes,asthesewerenotpredefined
study outcomes. We do, however, feel confident that infections
aremajoreventsthatwouldbenoticed.Furthermore,ifvalidity
was impaired we would expect this to be non-differential and
not to lead to an inaccurate estimate of the relative risk of
infection.
Conclusions and policy implications
Our systematic review and meta-analysis of data on infectious
outcomesinlargeplacebocontrolledstatintrialsdidnotprovide
evidence to support the hypothesis that statins decrease the risk
of infections. On the basis of previous observational studies,
many investigators have called for randomised trials of statins
for the prevention of infections. Our finding of an absence of
any protective effect shows that results from the observational
studies might be biased and that the arguments for setting up
such a trial are weakened. Besides this, given our observed
effect size of about zero, the sample size and follow-up time
required for adequate power to show a difference would be
approximately infinite. Furthermore, such a trial could entail
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RESEARCHwithholding statin treatment for a long period from people with
an indication for such treatment. In our opinion, such a study
would be unethical. According to Clinicaltrials.gov, numerous
randomised clinical trials with long term use of statins are
planned or recruiting patients. A better approach could be to
push reporting of infectious outcomes in detail whenever statin
trials are undertaken. This would have better prospects for
identifying subgroups in whom there may be effects worthy of
additional testing in a focused randomised trial.
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RESEARCHWhat is already known on this topic
Hydroxymethyl glutaryl coenzyme A reductase inhibitors, or statins, are widely used to prevent and treat cardiovascular disease
Statins have diverse anti-inflammatory and immunomodulatory effects
Observational studies have reported a decreased risk of infections for people taking statins, but biased estimations in these studies
cannot be ruled out
What this study adds
In this systematic review and meta-analysis of randomised placebo controlled trials, statins had no effect on the risk of infections
The absence of any evidence towards a beneficial effect of statins on risk of infection in large placebo controlled trials potentially negates
the causal effect reported in observational studies
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Table 1| Baseline characteristics of randomised controlled trials of statins included in analysis of infections and infection related mortality
Mean age
(years)
Median
follow-up
(years) Drug and daily dose (mg) Primary outcome Details of participants Study
64 3.2 Rosuvastatin 10 mg v placebo Time to major cardiovascular event 2773 undergoing
haemodialysis
Fellstrom 2009
18
73 2.7 Rosuvastatin 10 mg v placebo Composite of cardiovascular event (fatal
or non-fatal)
5011 with coronary heart
disease
Kjekshus 2007
19
63 4.9 Atorvastatin 80 mg v placebo Time to non-fatal or fatal stroke 4731 with previous stroke or
transient ischaemic attack
Amerenco 2006
20
68 3.9 Rosuvastatin 10 mg v placebo Time to death or admission for
cardiovascular event
4574 with chronic heart failure GISSI-HF 2008
21
66 4 Atorvastatin 20 mg v placebo Composite of cardiovascular events and
death from cardiac causes
1255 with diabetes undergoing
haemodialysis
Wanner 2005
22
68 2 Atorvastatin 10 mg v placebo All cause mortality, myocardial
infarction, coronary artery bypass
surgery, percutaneous transluminal
coronary angioplasty
143 with renal disease Stegmayr 2005
17
48 6.7 Fluvastatin 40 mg v placebo First major adverse cardiac event 1652 after renal transplant Holdaas (ALERT
extension*) 2005
23
60 3.9 Fluvastatin 80 mg v placebo Time to major adverse cardiac event 1677 with chronic heart
disease
Serruys 2002
24
62 3.9 Atorvastatin 10 mg v placebo Time to major adverse cardiac event 2838 with diabetes Newman 2008
25
61 1 Simvastatin 20 mg v placebo Composite of major atherosclerotic
events (myocardial infarction, death
from coronary heart disease, stroke)
5245 with renal disease Study of Heart and
Renal Protection†
2010
26
59 1 Atorvastatin 10-80 mg v
placebo
Percentage change from baseline in
lumbar (L1-4) spine bone mineral
density
626 postmenopausal women Bone 2007‡
27
*Publication of two year extension of original study. ALERT trial had a follow-up of 5.1 years, which was included in average.
†After one year a re-randomisation followed and intervention changed. Study continued until four years’ follow-up with intervention of placebo versus ezetimibe
or simvastatin.
‡118, 121, 124, and 122 participants received atorvastatin 10 mg, 20 mg, 40 mg, and 80 mg, respectively.
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RESEARCHTable 2| Quality assessment of randomised controlled trials included in meta-analysis of infections
Loss to follow-up
(%) Withdrawal rate (%)
Blinding of
participants
and staff Adverse event monitoring
Allocation
concealment
Sequence
generation Study Placebo Statin Placebo Statin
0 0 29.5 29.1 Double blinded Assessment of safety and efficacy at three
and six months and every six months
thereafter until end of study
Unclear Randomised* Fellstrom
(AURORA)
18 28-30
NR NR 21.9 19.5 Double blinded Assessment of adverse events at six weeks
and three months and every three months
thereafter. Additional questionnaire on
muscle symptoms requested
Adequate Adequate, computer
random generation
Kjekshus
(CORONA)
19 31
0.42 0.63 4.4 3.3 Double blinded Assessment of adverse events and blood
chemistry tests at 1, 3, 6, and 12 months
and than every six months until end of trial
Unclear Randomised* Amarenco
(SPARCL)
20 32 33
0.04 0.13 1.3 1.1 Double blinded Assessment of serious adverse events
(defined as fatal, life threatening, requiring
or prolonging hospital stay, permanently
disabling or incapacitating, which may
jeopardise participant or which may require
medical or surgical intervention) related
and not related to study drugs
Adequate Adequate, computer
random generation
GISSI-HF
21 34 35
0.16 0 23.6 22.9 Double blinded Assessment of serious adverse events
continuously, and data recording at four
weeks and then every six months
Adequate Adequate, computer
random generation
Wanner (4D)
22 36
37
0 1.4 8.2 28.6 Not blinded Adverse events and liver tests monitored
at 1, 3, 6, 12, 18, 24, 30, and 36 months of
follow-up
Adequate Adequate, computer
random generation
Stegmayr
17
0.38 0.29 0.95 1.5 Double blinded Assessment of clinically and laboratory
adverse events, at six weeks and every six
months thereafter
Adequate Adequate, computer
random generation
Holdaas (ALERT
extension†)
23 38 39
1.20 0.83 44.2 34.6 Double blinded Assessment of adverse events at six weeks
and every six months thereafter
Adequate,
central
allocation
Adequate Serruys
24 40
1.13 0.56 NR NR Double blinded Assessment of adverse events monthly for
first three months, then at six months, and
thereafter every six months
Adequate Adequate, computer
random generation
Newman,
(CARDS)
25 41 42
NR NR NR NR Double blinded Assessment of early adverse effects at two
and six months and every six months
thereafter
Unclear Randomised* Study of Heart
and Renal
Protection
26
NR NR 27.7 27.6 Double blinded Assessment of adverse events at
occurrence
Adequate Adequate, computer
random generation
Bone
27
NR=not reported.
*Exact method not described.
†Publication of two year extension of original study.
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RESEARCHTable 3| Data on infection related adverse events and infection related mortality from randomised controlled trials of statins
Source of data
Infection related mortality Infection related adverse events
Study source Type of infection
No of events in
placebo group
No of events in
intervention
group Type of infection
No of events in
placebo group
No of events in
intervention
group
Published NR 100 105 Bronchitis, pneumonia,
nasopharyngitis, and
urinary tract infections
956 976 Fellstrom
18
Published NR 68 54 NR 370 344 Kjekshus
19
Published NR 20 26 NR 439 414 Amarenco
20
Published as well
as provided by
authors
Respiratory tract
infections, sepsis,
and other
infections
14 21 Respiratory tract
infections, urinary tract
infections, sepsis,
hepatobiliary infections,
and other infections
160 191 GISSI-HF
21
Published NR 68 60 NR NR NR Wanner
22
Published NR 7 4 NR NR NR Stegmayr
17
Published NR 35 34 NR NR NR Holdaas (ALERT
extension*)
23
Published Sepsis 3 1 NR NR NR Serruys
24
Published NR NR NR NR 9 8 Newman
25
Published NR NR NR Infective hepatitis 6 1 Study of Heart and
Renal Protection
26
Published NR NR NR Respiratory tract infections
and urinary tract infections
32 129‡ Bone†
27
NR=not reported.
*Causes of death by original treatment group after open label extension, in which all participants were offered fluvastatin treatment, based on intention to treat
population.
†Study group receiving intervention (statin) was four times as large as placebo group.
‡Total of 25, 25, 41, and 38 participants experienced infections in groups receiving atorvastatin 10 mg, 20 mg, 40 mg, and 80 mg, respectively.
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Fig 1 Flow of participants through review
Fig 2 Meta-analysis of statin treatment and risk of infections in randomised controlled trials
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